CELZ - Creative Medical Technology Holdings Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The market valuation dynamics for Creative Medical Technology (CELZ) based on the EV/EBITDA metric is 0.00. The development of male infertility treatments is currently in the testing phase, while the expansion of research is driving up patent costs. The management team is betting on the protection of intellectual property and the transparency of trial data. The company's image is built on creating innovative cellular products to combat reproductive pathologies.
CELZ (creativemedicaltechnology.com): analytical breakdowns and indicator data
Investors view Creative Medical Technology (CELZ) as a high-risk biotech firm characterized by volatile earnings and a dependence on external financing. The enterprise value to EBITDA ratio allows for the removal of debt distortions from the valuation to determine the actual value of the business relative to its operating cash flow. An analysis of the EV/EBITDA level over the time interval reveals a critical overpayment for assets amid patent disputes and a lack of revenue.
